DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 32,498 Shares

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $70.69 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock’s fifty day moving average price is $83.99 and its two-hundred day moving average price is $76.85. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $27.62 billion, a price-to-earnings ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DXCM shares. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

Institutional Trading of DexCom

Several large investors have recently modified their holdings of DXCM. Covestor Ltd grew its holdings in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of DexCom by 8.8% during the 3rd quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company’s stock worth $864,000 after purchasing an additional 1,046 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of DexCom by 129.1% during the 3rd quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company’s stock worth $688,000 after purchasing an additional 5,787 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of DexCom during the 3rd quarter worth $221,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.